March 12, 2024

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

March 12, 2024

SIGA Declares Special Cash Dividend of $0.60 Per Share

March 05, 2024

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

January 22, 2024

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

November 07, 2023

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

October 26, 2023

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

October 23, 2023

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

September 06, 2023

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

August 08, 2023

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

July 27, 2023

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

July 27, 2023

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

June 27, 2023

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

May 04, 2023

SIGA Reports Financial Results for Three Months Ended March 31, 2023

May 04, 2023

SIGA Declares Special Cash Dividend of $0.45 Per Share

April 27, 2023

SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results

March 02, 2023

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

February 23, 2023

SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

January 17, 2023

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

November 03, 2022

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

October 27, 2022

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

October 12, 2022

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

September 29, 2022

SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

September 26, 2022

SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

August 09, 2022

SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®

August 04, 2022

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022

July 28, 2022

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

July 15, 2022

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

July 12, 2022

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

July 08, 2022

SIGA Technologies Receives Approval from UK for Tecovirimat

June 23, 2022

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

June 22, 2022

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

May 19, 2022

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

May 12, 2022

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®

May 05, 2022

SIGA Reports Financial Results for Three Months Ended March 31, 2022

May 05, 2022

SIGA Declares Special Dividend of $0.45 Per Share

April 28, 2022

SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results

March 03, 2022

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021

March 02, 2022

SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials

February 24, 2022

SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results

January 25, 2022

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

January 18, 2022

SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

January 10, 2022

SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat

December 01, 2021

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

November 16, 2021

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat

November 04, 2021

SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021

October 28, 2021

SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results

September 13, 2021

SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®

September 07, 2021

SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021

August 05, 2021

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021

July 29, 2021

SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results